The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis

被引:0
|
作者
Axel Svedbom
Johan Dalén
Moa Ivergård
Rebekah H. Borse
Christopher M. Black
Karin Luttropp
Sumesh Kachroo
机构
[1] ICON Clinical Research,Real
[2] Merck & Co.,World Strategy and Analytics
[3] Inc.,Center for Observational and Real
关键词
Cost–benefit analysis; Medication persistence; Economic evaluation; Ankylosing spondylitis; Bechterew’s disease; I120;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:45 / 54
页数:9
相关论文
共 50 条
  • [1] The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
    Svedbom, Axel
    Dalen, Johan
    Ivergard, Moa
    Borse, Rebekah H.
    Black, Christopher M.
    Luttropp, Karin
    Kachroo, Sumesh
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 45 - 54
  • [2] THE VALUE OF PERSISTENCE IN TREATMENT WITH SUBCUTANEOUS TNF-ALPHA INHIBITORS FOR ANKYLOSING SPONDYLITIS
    Ivergard, M.
    Dalen, J.
    Svedbom, A.
    Black, C. M.
    Borse, R. H.
    Kachroo, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 840 - 841
  • [3] TNF-alpha inhibitors for ankylosing spondylitis
    Maxwell, Lara J.
    Zochling, Jane
    Boonen, Annelies
    Singh, Jasvinder A.
    Veras, Mirella M. S.
    Ghogomu, Elizabeth Tanjong
    Jandu, Maria Benkhalti
    Tugwell, Peter
    Wells, George A.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (04):
  • [4] DETERMINANTS OF 12-MONTHS PERSISTENCE IN ANKYLOSING SPONDYLITIS PATIENTS INITIATING SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Fautrel, B.
    Belhassen, M.
    Hudry, C.
    Woronoff, M. -C.
    Gouyette, N.
    Clement, A.
    Van Ganse, E.
    Tubach, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 754 - 755
  • [5] Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Lamezec, Liliane
    Gouyette, Najat
    Ginoux, Marine
    Van Ganse, Eric
    Tubach, Florence
    Fautrel, Bruno
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [6] TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
    I Orbán
    K Sevcic
    EV Kiss
    [J]. Pediatric Rheumatology, 9 (Suppl 1)
  • [7] TREATMENT PERSISTENCE OF SUBCUTANEOUS TNF-ALPHA INHIBITORS AND JAK INHIBITORS AMONG AUSTRALIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Puig, Andrea
    Chien, Tirian
    O'Sullivan, Catherine
    [J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 24 - 24
  • [8] Neurosarcoidosis Induced by TNF-alpha Inhibitor in a Patient with Ankylosing Spondylitis
    Pak, Daod
    Askari, Elham
    Treidler, Simona
    [J]. NEUROLOGY, 2023, 100 (17)
  • [9] Determinants of 12-Months Persistence in Ankylosing Spondylitis Patients Initiating Subcutaneous TNF-α Inhibitors
    Fautrel, Bruno
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Gouyette, Najat
    Clement, Aurore
    Van Ganse, Eric
    Tubach, Florence
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 514 - 515
  • [10] TNF-α inhibitors for the treatment of ankylosing spondylitis
    Wang, Michael Y.
    [J]. NEUROSURGERY, 2006, 59 (02) : N7 - N7